MedTrace Logo

Assessment of Safety and Efficacy of CCP

NCT04542941 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 136

Last updated 2021-01-15

No results posted yet for this study

Summary

Currently there are no proven treatments or vaccines for COVID-19 and care of the COVID patients is largely supportive involving treatment of symptoms such as fever with antipyretics, secondary bacterial chest infection with antibiotics and meticulous management of comorbid conditions.

Several repurposed and new drugs have been investigated for treatment of COVID-19, however, none have been confirmed to be efficacious. These drugs include the antimalarials (chloroquine and hydroxychloroquine), antivirals such as remdesivir and favipiravir and antiretroviral combination therapies such lopinavir/ritonavir.

There is emerging evidence to support the use of COVID convalescent plasma for the treatment of COVID-19. There is need to leverage the blood transfusion services in countries and this is beginning to happen on the continent.

Conditions

  • Covid19

Interventions

BIOLOGICAL

COVID Convalescent Plasma

Plasma collected from recovered COVID 19 individuals

Sponsors & Collaborators

  • Uganda Blood Transfusion Services

    collaborator UNKNOWN

  • Joint Clinical Research Center

    collaborator OTHER

  • Uganda Peoples Defence Forces Medical Services

    collaborator UNKNOWN

  • Mulago Hospital, Uganda

    collaborator OTHER

  • Makerere University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-16
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • Uganda

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04542941 on ClinicalTrials.gov